在全球经济一体化的浪潮中，香港凭借其独特的地理位置、完善的法律体系、自由的贸易环境以及高度国际化的金融市场，成为连接中国内地与世界的重 要枢纽。在这样的背景下，香港公司在跨境业务中扮演着愈发关键的角色，其作用渗透到税务筹划、跨境贸易、海外上市等多个重要领域，为企业开展跨 国经营提供了强有力的支持。 此外，香港拥有高效的物流网络和世界级的港口设施，货物通关速度快，能确保商品及时送达全球各地。香港公司依托这些优势，可帮助企业优化供应链 管理，降低物流成本，提升跨境贸易的整体运营效率。 香港是全球重要的金融中心之一，其证券市场成熟、规范，具有高度的国际化和流动性，为企业海外上市提供了理想场所。 对于内地企业来说，通过香港公司实现海外上市具有诸多好处。香港联交所的上市标准相对灵活，对不同行业、不同规模的企业都有相应的上市通道，尤 其是对科技创新型企业和新经济企业较为友好。内地企业可通过重组，将核心业务注入香港公司，以香港公司为主体在香港联交所上市，从而获得国际资 本市场的资金支持。 VIE架构是企业境外上市的常用架构，其是由开曼公司在香港注册一个全资子公司，再经由这个香港公司在国内注册设立一个外商投资企业（WFOE） ...

大众网记者 潘超 青岛报道 6月20日下午，由中国光晖投资控股有限公司（以下简称"光晖控股"）主办，国际金融研究协会 （IFRA）、中国企业报和盈达集团等联合主办的"金融变革，共探新途"国际金融论坛在青岛西海岸喜 来登酒店举行。本次论坛聚焦全球金融体系深度调整背景下的改革路径，吸引了来自政策机构、跨国银 行、产业资本及学术界的200余位代表，共同探讨金融开放、跨境协作与产业升级的协同发展之道。 光晖控股总经理崔允峰在致辞中表示，在当前全球经济市场低迷、企业全球化浪潮中，海外上市不仅是 企业获取资本的有效途径，更是展示中国经济韧性与创新实力的窗口。他认为国内企业要把握政策红 利，善用市场规则，以国际化视野拥抱机遇，才能在全球资本市场的舞台上书新篇章。 在圆桌会议阶段，与会专家认为，当前全球经济正经历"碎片化"与"重构"的双重挑战。国际货币基金组 织（IMF）最新预测显示，2025年全球经济增长率或低于3%，而中国作为世界第二大经济体，仍以5% 以上的增速为世界注入稳定力量。这一背景下，中国证监会近期明确"鼓励企业依法合规境外上市"的政 策导向，既是对企业全球化布局的支持，更是中国深化金融开放、参与国际规则制定的 ...

Core Viewpoint - The company *ST Shuangcheng (002693)* has received marketing approval for Eptifibatide injection from the Australian Therapeutic Goods Administration, which is expected to enhance its overseas market expansion and improve performance [1] Group 1: Product Approval - Eptifibatide injection is indicated for patients undergoing non-emergency percutaneous coronary intervention and coronary artery stenting, as well as for treating unstable angina or non-Q-wave myocardial infarction [1] - The product has already received marketing approval from the US FDA and is widely sold globally [1] Group 2: Market Impact - The approval in Australia will assist the company in expanding its overseas market presence [1] - The company cautions that export sales of the drug may be influenced by market demand, policy environment, exchange rates, and market competition, indicating potential uncertainties [1]

Group 1 - The company will participate in the "2024 Annual Performance Briefing and Investor Reception Day" on May 13, 2025, to enhance communication with investors regarding its annual report and other key topics [1] - The company has received marketing authorization from the Therapeutic Goods Administration (TGA) in Australia for its injectable drug Bivalirudin, which is indicated as an anticoagulant for high-risk acute coronary syndrome patients [3][4] - The injectable Bivalirudin has previously received approvals from various regulatory bodies, including the FDA in the United States and the Saudi Arabian SFDA [5] Group 2 - The company's stock has experienced abnormal trading fluctuations, with a cumulative price deviation exceeding 12% over two consecutive trading days [9] - The company has confirmed that there are no undisclosed significant matters that could affect its stock price, and it has conducted a thorough review of its recent trading activity [10][11] - The company has been placed under a delisting risk warning due to negative financial results, with the lowest of its audited profit total, net profit, and net profit after non-recurring gains and losses being negative, and revenue below 300 million [12]